← Research Hub
M&A dealsLicensing dealsIPO trackerFunding rounds

Biotech IPO Tracker 2026

Live tracker of biotech and biopharma IPOs in 2026 — therapeutic area, lead asset, stage at IPO, pricing date, offer price, gross proceeds, approximate market cap at listing, and aftermarket performance.

Crossover and pre-IPO rounds are often the first sign of the next listing. Follow them in private biotech financing rounds for 2026.

● 31 IPOs pricedLast updated 16 November 2026
31
IPOs priced
~$9.3B
Total gross proceeds
17 : 14
Above : Below issue
+662.7%
Best performer
2026 IPO Market Snapshot
WindowWindward closed its 13 November debut at US$28.50, up 67.6% from its US$17 offer price. Its US$175M gross IPO proceeds exclude the separate US$50M Sanofi placement and unexercised option. Bambusa and Aspen closed at US$16.09 (up 0.6%) and US$12.59 (down 16.1%) respectively; fixed debut returns remain -6.3% and -0.7%.
LargestParabilis leads at $770.5M, ahead of Kailera at $718.8M, ADARx at $513.2M, Kardigan at $460.0M, Braveheart at $439.9M, Generate at $400.0M, Latigo at $397.4M, Eikon at $381.0M and Aktis at $365.4M. ~$9.3B raised across 31 US-listed biotech IPOs.
StandoutVeradermics leads at +662.7%, followed by Hemab +127%, SpyGlass +106%, Alamar +81% and Lycia +73%. All 31 IPOs are marked to the 13 November close: 17 above issue and 14 below.
Bifurcation14 trade below issue, led by Eikon (67%), Agomab (60%), Electra (41%) and Latigo (27%). City is up 0.6% from its offer price; Iambic is down 18.1%.
Get IPO alerts as they land

The tracker refreshes weekly. The daily BioBucks tape flags new filings, launches, pricings, discounts, upsizes, and aftermarket movers every morning.

CompanyTherapeutic areaLead assetPhase at IPOPricing dateOffer priceProceedsMCAP at IPO1-dayvs. offer
Windward BioImmunology / Respiratory disease / DermatologyWIN378 (ultra-long-acting anti-TSLP antibody; severe asthma and COPD)Phase 2/312 Nov 2026$17.00$175.0M—+67.6%+67.6%
Bambusa TherapeuticsImmunology / InflammationBBT001 (IL-4Rα / IL-31 bispecific; atopic dermatitis and chronic spontaneous urticaria)Phase 229 Oct 2026$16.00$168.9M$815.1M-6.3%+0.6%
Aspen NeuroscienceNeuroscience / Parkinson’s diseaseSasineprocel (autologous iPSC-derived dopaminergic neuron cell therapy)Phase 1/2a29 Oct 2026$15.00$140.6M$436.2M-0.7%-16.1%
Lycia TherapeuticsImmunology / Allergy / Extracellular protein degradationLCA-0061 (IgE-degrading cataLYTAC; food allergy)Phase 122 Oct 2026$18.00$365.1M$990.6M+66.7%+73.3%
City TherapeuticsCardiovascular / Thromboembolic disease / RNA interferenceCITY-FXI (Factor XI-targeting siRNA)Phase 115 Oct 2026$18.00$200.0M$931.0M+24.4%+0.6%
Iambic TherapeuticsOncologyIAM1363 (brain-penetrant HER2 inhibitor)Phase 114 Oct 2026$16.00$150.0M$758.4M+18.2%-18.1%
TRexBioImmunology / Atopic dermatitisTRB-061 (TNFR2 agonist Fc-fusion protein to expand tissue regulatory T cells)Phase 1b08 Oct 2026$14.00$116.7M$384.2M0.0%-2.4%
Retension PharmaceuticalsCardiovascular / HypertensionRTN-001 (PDE5 inhibitor for uncontrolled hypertension)Phase 2b08 Oct 2026$12.00$45.0M$100.0M-12.3%+2.3%
ADARx PharmaceuticalsRare disease / Hereditary angioedema / RNA interferenceOnvuzosiran (siRNA for prevention of hereditary angioedema attacks)Phase 324 Sep 2026$17.00$513.2M~$1.81B+13.8%-16.5%
Electra TherapeuticsImmunology / Hyperinflammatory disease (secondary haemophagocytic lymphohistiocytosis)Ipsoprubart (ELA026) — in a global registrational programme in secondary HLH, with a separate Phase 1 in relapsed/refractory T-cell and NK-cell malignanciesPhase 2/317 Sep 2026$15.00$350.0M~$941.5M-11.7%-41.1%
VogenxMetabolic disease / Endocrinology (post-bariatric hypoglycemia, gastroparesis, GIP-dependent Cushing’s syndrome)Mizagliflozin (oral selective SGLT1 inhibitor; lead indication post-bariatric hypoglycemia, with gastroparesis and GIP-dependent Cushing’s syndrome behind it)Phase 211 Aug 2026$13.00$93.4M~$180.9M0.0%+28.2%
Latigo BiotherapeuticsPain / Non-opioid analgesia (acute and chronic pain)LTG-001 (oral Nav1.8 inhibitor; moderate-to-severe acute pain, positive 343-patient abdominoplasty Phase 2b published in NEJM)Phase 3-ready06 Aug 2026$18.00$397.4M~$1.3B+1.0%-27.2%
BlossomHill TherapeuticsOncology / Targeted small molecules (EGFR-mutant NSCLC, R/R AML)BH-30643 (macrocyclic, non-covalent, brain-active, mutant-selective OMNI-EGFR inhibitor; EGFR- and HER2-mutated NSCLC, initial focus on the C797S resistance population after 3rd-generation EGFR TKI). Second clinical asset BH-30236, a macrocyclic CLK inhibitor in R/R AML and higher-risk MDSPhase 1/206 Aug 2026$16.00$168.3M~$490.3M0.0%-12.4%
Braveheart BioCardiovascular / Genetic cardiomyopathyBHB-1893 (oral cardiac myosin inhibitor licensed from Hengrui; obstructive hypertrophic cardiomyopathy)Phase 3-ready05 Aug 2026$18.00$439.9M~$1.3B+66.0%+9.0%
Attovia TherapeuticsImmunology / Dermatology (chronic pruritus, atopic dermatitis)ATTO-1310 (half-life-extended anti-IL-31 ATTOBODY biparatopic nanobody; chronic pruritus and high-itch atopic dermatitis)Phase 1b04 Aug 2026$17.00$332.4M~$767M+28.8%-11.0%
ApnimedSleep medicine / Sleep-related breathing disordersAD109 / Oxnimbi (oral aroxybutynin-atomoxetine; obstructive sleep apnea, PDUFA 28 Feb 2027)Phase 3 complete30 Jul 2026$16.00$220.8M~$680M+56.3%+5.8%
Scribe TherapeuticsCardiovascular / Gene editing (epigenetic silencing)PCSK9- and Lp(a)-lowering epigenetic silencing candidate (lipid-lowering genetic medicine)Phase 123 Jul 2026$15.00$148.0M~$440M+44.3%+9.1%
KardiganCardiovascular / Precision medicinesdanicamtiv, ataciguat and tonlamarsen (three late-stage cardiovascular programs)Phase 2b/317 Jun 2026$16.00$460.0M~$1.4B+37.5%-13.6%
Parabilis MedicinesOncology / Peptide therapeutics / Hard-to-drug targetszolucatetide (clinical-stage Helicon peptide; desmoid tumors and other solid tumors)Phase 1/209 Jun 2026$20.00$770.5M~$2.3B+58.0%+42.2%
Odyssey TherapeuticsAutoimmune / InflammationOD-001 (oral RIPK2 inhibitor; ulcerative colitis)Phase 207 May 2026$18.00$289.8M~$900M-8.8%+6.3%
Hemab TherapeuticsRare bleeding disorderssutacimig / HMB-001 (bispecific antibody; Glanzmann thrombasthenia)Phase 3-ready30 Apr 2026$18.00$346.7M~$841M+88.9%+127.0%
Seaport TherapeuticsNeuropsychiatryGlyphAllo (oral neuroactive steroid; major depressive disorder)Phase 2b30 Apr 2026$18.00$260.0M~$912M+10.2%+11.0%
Avalyn PharmaRare lung diseaseAP01 (inhaled pirfenidone; idiopathic pulmonary fibrosis)Phase 2/329 Apr 2026$18.00$345.0M~$813M+63.8%+68.2%
Kailera TherapeuticsObesity / Metabolic diseaseribupatide (GLP-1/GIP dual agonist; obesity)Phase 316 Apr 2026$16.00$718.8M~$2.0B+62.5%-17.1%
Alamar BiosciencesProteomics / DiagnosticsNULISA / ARGO HT System (ultrasensitive proteomics platform)Commercial16 Apr 2026$17.00$219.9M~$1.53B+33.0%+81.2%
Generate BiomedicinesInflammation / Immunology / OncologyGB-0895 (half-life-extended anti-TSLP; severe asthma)Phase 326 Feb 2026$16.00$400M~$2.2B-21.0%-24.6%
SpyGlass PharmaOphthalmologyBIM-IOL System (bimatoprost drug-pad IOL; OAG/OHT)Phase 305 Feb 2026$16.00$172.5M~$842M+65.0%+105.5%
Agomab TherapeuticsInflammation / FibrosisAGMB-129 / ontunisertib (oral ALK5 inhibitor; fibrostenosing Crohn's)Phase 2a05 Feb 2026$16.00$208.0M~$780M-8.4%-60.3%
Eikon TherapeuticsOncologyEIK1001 (TLR7/8 agonist; advanced melanoma)Phase 2/304 Feb 2026$18.00$381M~$972M-16.7%-66.8%
VeradermicsAesthetic dermatologyVDPHL01 (extended-release oral minoxidil; androgenetic alopecia)Phase 303 Feb 2026$17.00$294.8M~$596M+122.1%+662.7%
Aktis OncologyOncology225Ac-AKY-1189 (Nectin-4-targeting radioligand; solid tumors)Phase 1b08 Jan 2026$18.00$365.4M~$945M+24.4%-7.7%

Subscribe to see the full deal sheet

BioBucks is free. Enter your subscriber email below to unlock the full tracker - or subscribe in seconds.

Not subscribed yet?
Subscribe - takes 30 seconds
Methodology

"Proceeds" reflects gross IPO proceeds before fees and expenses, including confirmed full or partial exercises of underwriters' options disclosed by 14 October 2026. Concurrent private placements are excluded. ADARx includes its option closed on 1 October. Options are not assumed exercised based on share-price performance. Proceeds are attributed to each IPO pricing cohort, not cash received strictly before quarter-end. "MCAP at IPO" is approximate market capitalisation at listing. "vs. offer" is based on share prices as of the 13 November 2026 refresh and will move with the market. Rows are sorted in reverse chronological order by pricing date. For how listing valuations and share counts are calculated, see valuation and fully diluted share terms.

Returns use Yahoo Finance’s 13 November 2026 regular-session closing quotes, excluding after-hours trades. City and Iambic debuted on 16 and 15 October respectively. Their IPO market caps, together with TRexBio and Retension, use final-prospectus post-offering basic share counts multiplied by the offer price, excluding unexercised options and equity awards. Gross IPO proceeds include confirmed exercised underwriters’ options disclosed by 14 October 2026, including ADARx’s option closed on 1 October; concurrent private placements are excluded. Unconfirmed option exercises are not assumed. Lycia is a new addition with US$365.1M proceeds including its confirmed option exercise at the 26 October closing; existing IPO proceeds are otherwise unchanged. Bambusa and Aspen priced on 29 October for US$168.9M and US$140.6M respectively, excluding unexercised options. Their market caps use filed pro forma basic share counts plus confirmed IPO shares at the offer price; Bambusa’s filing includes a liquidity-event RSU settlement assumption. Both debuted on 30 October; their fixed first-day returns use that session’s closing prices, while offer-to-current returns use 13 November closes. All 31 IPOs are marked to the 13 November close. Windward priced on 12 November at US$17 for US$175M gross, excluding the separate US$50M Sanofi placement and unexercised option. It debuted on 13 November at a closing price of US$28.50, a 67.6% gain from offer. Its market cap remains — pending verification.